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s the population in the USA and other devel-
oped nations ages, the number of older persons with a
major psychiatric disorder is expected to increase.It has
been estimated that by the year 2030,the number of per-
sons over age 65 with a major psychiatric disorder will be
roughly equal to the number of people aged 30 to 44 with
a similar disorder.
1 This demographic trend has major
implications for both the costs and logistics of caring for
this growing group of older persons with major psychi-
atric disorders.This article will discuss several emerging
areas of research and clinical care that are particularly
pertinent to older persons with schizophrenia.These top-
ics will include the public health challenge and the cost
of care for older patients with schizophrenia.We will also
discuss the course of schizophrenia in late life,including
clinical differences between early-and late-onset schizo-
phrenia, with respect to neurocognitive decline and
remission,and the nature and importance of comorbid
medical conditions and medical care for older persons
with schizophrenia.Finally,we will report the results of
the only randomized clinical trial that compared two
atypical antipsychotics in older patients with schizophre-
nia,and discuss recent regulatory actions with respect to
the side effects of atypical antipsychotics that may be of
particular concern in late-life schizophrenia.
By convention,the geriatric population is considered to
include those aged 65 and older.However,the terms “later
life”or “late onset”have come to represent different age-
groups when discussing schizophrenia. Late-life schizo-
phrenia comprises two distinct groups:those individuals
who were diagnosed with schizophrenia early in life (late
adolescence or young adulthood) and who are now mid-
dle-aged; and those who are diagnosed when they are
elderly (45 years or older).Those individuals who are diag-
nosed with schizophrenia at the age of 45 or older are clas-
sified as late-onset schizophrenia.Our center has included
45
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Schizophrenia in late life is emerging as a major public
health concern worldwide. We discuss several areas of
research and clinical care that are particularly pertinent
to older persons with schizophrenia, including the pub-
lic health challenge and the cost of care. We then discuss
clinical issues relevant to late-life schizophrenia (course
of illness and cognition), medical care and comorbidity
in older psychiatric patients (general and illness-related),
and treatment concerns related to the use of atypical
antipsychotics in older persons with psychosis (efficacy
and side effects). Clinical care for this ever-increasing seg-
ment of our population requires special consideration of
the unique characteristics of older persons with schizo-
phrenia.  
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:45-52.both middle-aged and elderly persons with schizophrenia,
those with early or late onset. The average age of our
cohort is around age 60 and we use no upper age cutoff.
The public health challenge
A recent report by Bartels and colleagues examined the
annual health care costs for adults with schizophrenia,
depression,dementia,or physical illnesses in one small US
state (New Hampshire).
2 In general,except for dementia,
costs of care increased with the age of patients,with those
over 85 incurring the greatest per-capita expense.Among
people aged 65 or over,annual per-person care for those
with schizophrenia,$40 000 or more,was the most costly:
(about 50% higher than for those with depression and
about three times higher than for those receiving care for
only physical illnesses).The patients with schizophrenia
incurred higher annual costs in all age-groups compared
with depression or medical conditions.The cost-by-age data
were different for patients with dementia,where younger
patients incurred higher costs.However,among patients
over age 65,the cost of care was higher for the patients with
schizophrenia compared with those with dementia.
This report also calculated the costs associated with the var-
ious treatment settings,such as outpatient clinics,inpatient
hospitals,and nursing homes,where people with schizo-
phrenia in each age cohort received their treatment.
Among the younger patients (aged 19 to 44),outpatient
mental health treatment consumed approximately 50% of
the annual expenditures ($10 244 in outpatient costs,
$20 066 in total costs).In contrast,in those patients aged 75
and older, only 5% of the annual expenditures were for
outpatient care ($1755 of $34 320),and the vast majority of
expenditures were for nursing home care ($28 395 or 83%).
Even in old age,schizophrenia is expensive.The costs of
treating schizophrenia increase with age,across the entire
adult life span.The need for this level of care is a reflection
of the degree of symptomatology and disability in these
patients.As Bartels et al point out,interventions that opti-
mize functioning and decrease use of nursing homes are
particularly needed for older patients with schizophrenia.
Course of schizophrenia in late life
The clinical presentation of older persons with schizo-
phrenia differs somewhat from that of younger persons,
and the course of this disorder into old age sheds light on
some unresolved cognitive and social issues.In this sec-
tion,we discuss the clinical differences between patients
with early- versus late-onset schizophrenia,review the
emerging research describing changes in symptoms and
neuropsychological deficits over time,and consider a new
perspective on remission from schizophrenia.
Age of onset of schizophrenia
Since the Diagnostic and Statistical Manual of Mental
Disorders, Third Edition-Revised (DSM-III-R), “late-
onset”schizophrenia has been defined as onset of symp-
toms after the age of 44,
3 and accounts for approximately
15% to 20% of all cases of schizophrenia.
4 Most patients
with late-onset schizophrenia have onset of illness during
middle age.Onset after age 65 usually signifies very-late-
onset schizophrenia-like psychosis,which is typically sec-
ondary to general medical conditions,such as dementia or
other neurodegenerative disorders.
5 Women are more
likely to have late-onset schizophrenia than men.In addi-
tion,persons with late-onset schizophrenia tend to have
better premorbid functioning,fewer negative symptoms,
and less severe neurocognitive impairments.Although the
conventional wisdom has been that the symptoms of schiz-
ophrenia progress with age, recent investigations have
found that many symptoms of schizophrenia improve with
age. Older patients typically have fewer and less severe
positive symptoms than their younger counterparts
6;neg-
ative symptoms, however, tend to persist into late life.
5
Finally, patients with late-onset schizophrenia typically
require lower daily doses of antipsychotics compared with
patients with an early onset of the disorder.
7,8
Neuropsychological changes over time
Schizophrenia is commonly associated with mild-to-mod-
erate neuropsychological deficits,
9 which,more than sever-
ity of psychopathology,are the most robust predictors of
functional independence,
10 including functional indepen-
dence among older patients with schizophrenia.
11-13 The
Kraepelinian notion of schizophrenia as dementia prae-
cox colored conventional thinking regarding the long-term
course of this disorder for many years,in that it was gen-
erally assumed that there was a progressive deterioration
in functioning as patients aged.However,with the excep-
tion of studies of chronically institutionalized “poor out-
come”patients,
14,15 who represent a small minority of the
contemporary population of older persons with schizo-
phrenia,
16 the weight of empirical data on the longitudinal
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fact documents a remarkably stable pattern of neuropsy-
chological functioning,
17,18 even among older patients with
schizophrenia, as well as those whose symptoms first
emerge in mid- to late life.
18,19 For instance, in a recent
study from our research center,we annually administered
a comprehensive neuropsychological test battery to 142
patients with DSM-III-R or DSM-IV diagnoses of schizo-
phrenia (confirmed with a structured clinical interview),
as well as 206 healthy comparison subjects.We found that
patients’ neuropsychological functioning remained stable
over follow-up periods of up to 5 years or more, even
among the subset whose positive or negative symptoms
deteriorated or improved over the follow-up periods,and
among those ages 65 or older, as well as those whose
symptoms onset in mid- to late life.In short,while patients
with schizophrenia as a group have worse neurocognitive
functioning than the general population,there does not
appear to be risk of greater than age-normal progressive
decline, at least among noninstitutionalized patients.
Moreover, given the importance of neuropsychological
abilities to independent functioning,these findings of sta-
bility suggest a reason for optimism about the long-term
prospects of maintaining a degree of functional indepen-
dence as patients age.
Informed consent and decisional capacity
Patients with schizophrenia are routinely asked to pro-
vide informed consent for their antipsychotic medication
treatment.However,because of the cognitive deficits,as
well as insight deficits, which are sometimes present
among those with schizophrenia,
9,20 some schizophrenia
patients may lack the capacity to provide independent
consent for treatment. On the other hand,empirical data
document considerable heterogeneity among older as
well as younger schizophrenia patients in terms of the
level of decisional capacity,
21-23 and age is not itself a
strong predictor of the level of decisional capacity among
such patients.
23-25 Nonetheless,due to the increased like-
lihood of medical comorbidity and polypharmacy present
in the older population,
26,27 together with the increased
physical frailty of some elderly persons,and the still rel-
atively limited empirical database on the safety and effi-
cacy of antipsychotic medications for use with “real-
world” elderly patients, the very nature of treatment
decisions and consent may be particularly complex in the
context of treating older patients with schizophrenia,and
thus consent issues are particularly salient.
The strongest predictors of impaired decisional capacity
tend to be level of cognitive deficits, and to a lesser
degree,severity of negative symptoms.
23,25,28,29Therefore,
when recommending treatment for patients with notable
cognitive deficits and/or substantial negative symptoms,
clinicians should be particularly alert to the possible pres-
ence of impaired consent capacity.One instrument that
can be helpful in further evaluating such patients is the
MacArthur Competence Assessment Tool for Treatment
(MacCAT-T).
22 The MacCAT-T involves a 15- to 20-
minute semistructured interview,which assesses a range
of consent-relevant topics,including the patient’s ability
to understand the nature of his or her condition and the
proposed treatment,his or her ability to apply (appreci-
ate the significance of) that information to his or her own
situation, and to consider the risks and benefits of the
proposed treatment relative to alternative choices,as well
as to express a clear and consistent choice.(See Dunn et
al,
30 in press,for a thorough review of this and other deci-
sional capacity instruments.) Issues of “competency”are
most commonly addressed when patients are refusing a
recommended treatment,but given the considerations
described above,there may be merit in considering deci-
sional capacity even when patients are accepting recom-
mended treatment, particularly when more than one
viable alternative is present with varying risk-benefit con-
siderations.
Remission
Despite the stability of cognitive functioning,the clinical
presentation of schizophrenia may vary over the course
of the illness.The symptoms and functioning in some per-
sons with schizophrenia will worsen over time,and many
will remain stable.Some,however,will improve.It should
be no surprise that remission from schizophrenia has
been found to range from 3% to 64% of patients
31;how-
ever, these prior reports used a variety of criteria to
define remission.
We developed a definition of remission that included the
following criteria
32:(i) previously meeting DSM-III-R or
DSM-IV criteria for schizophrenia or schizoaffective dis-
order;(ii) receiving a course specifier of “in full remis-
sion”;(iii) living independently for the prior 2 years;iv)
no psychiatric hospitalizations in the prior 5 years; (v)
current psychosocial functioning reported to be within
the “normal” range, confirmed by caregiver or other
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47informant; and (vi) currently not taking antipsychotic
medications, or taking less than 50% of prior highest
dose.We recognize that by including criteria other than
symptomatology (function,hospitalization,and medica-
tion) that our criteria may be considered stringent (see,
for example,Andreasen et al
33).
In the database of patients enrolled in our center,there
were a total of 155 patients over age 60 who were living
independently. Of these, 12 met the above criteria for
remission.Comparing the patients with remission with a
cohort of patients with symptomatic schizophrenia and a
second cohort of normal control patients, the patients
whose schizophrenia had remitted were found to have
psychopathology that was similar to the normal controls.
On measures of cognition,health-related quality of life,
and everyday functioning, the patients with remitted
schizophrenia were intermediate between normal con-
trols and patients with symptomatic schizophrenia.These
findings suggest that patients were not achieving a nor-
mal state of functioning,but rather were returning to a
premorbid state of suboptimal and somewhat impaired
function.
An important remaining question is what factors con-
tribute to remission,and what approaches to intervention
can enhance the likelihood of remission.There is consid-
erable promise in the expanded use of rehabilitation-ori-
ented psychosocial interventions in this regard.
34-36 Initial
results are promising with regard to improvement of func-
tion.The longer-term outcomes,including the achievement
of remission,remain open issues.
Medical conditions in older persons 
with schizophrenia
Until recently,a topic that has arguably received inade-
quate attention is comorbid medical conditions in peo-
ple with schizophrenia, including adequacy of medical
care and the prevalence of comorbid conditions.Medical
comorbidity is even more pertinent to older persons with
schizophrenia,given the increase in age-related disorders.
A series of articles by Druss and colleagues compared
the care that patients with schizophrenia received after
suffering a myocardial infarction (MI) with the care
received by persons with no mental illness.
37,38 Using the
proportion of patients who undergo cardiac catheteriza-
tion post-MI as a measure of quality of care (a proxy
measure that has been used in other investigations of
health disparities
39) they reported that,compared with
patients with no mental illness,patients with schizophre-
nia were 60% less likely to undergo a cardiac catheteri-
zation after an MI.
37 A second report found that these
same patients had a 30% greater 1-year mortality than
non–mentally ill patients. Approximately half of this
increased mortality was due to a lack of quality medical
treatment after the MI.
38
Work in our center
40 found that,in middle-aged and older
homeless patients with mental illness,those patients with
schizophrenia were less likely to receive primary and pre-
ventive care than patients with major depression.
Similarly,Himmelhoch and colleagues have shown that
the prevalence (22.6%) of chronic obstructive pulmonary
disease (COPD) was substantial in people with serious
mental illness and substantially higher than overall
national norms in the USA: the prevalence of chronic
bronchitis in the schizophrenia sample was 19.5% (com-
pared with the national rate of 6.1%) and emphysema
was 7.9% (compared with the national rate of 1.5%).
41
Conversely,we are aware of at least one report that indi-
cates that patients with schizophrenia may be receiving
quality medical care;this study found that patients with
schizophrenia had slightly better diabetes control than a
matched group of patients with no mental illness (using
hemoglobin A1c levels).
42
Among persons with schizophrenia,the most common
cause of death is heart disease (just like in the general
population),
43 yet it has been estimated that persons with
schizophrenia on average die 10 years earlier than the
general population.
44 The growing concerns about the
risk of diabetes,MI,and stroke in patients taking second-
generation antipsychotics has also increased the aware-
ness of the importance of comorbid medical conditions
in patients with schizophrenia.An investigation of midlife
adult patients with schizophrenia treated in a community
mental health center (mean age 44) found that diabetes
and lung disease were more common among persons
with schizophrenia than in the general US population.
45
Future research should examine whether these disorders
are also more prevalent among older persons with schiz-
ophrenia,or whether these disorders have an earlier age
of onset among persons with schizophrenia.
Preventive health care is another area of major concern
for all people with schizophrenia, especially the older
patients.Work in our center,
46 for example, has shown
that, compared with women with no known diagnosis,
middle-aged and older women with schizophrenia were
25% less likely to have had a pelvic examination and Pap
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likely to have had a mammogram in the past 2 years
(98% versus 68%). Considering that, at the time the
study was completed, hormone replacement therapy
(HRT) was much more widely recommended than it is
today, the women with schizophrenia were 22% less
likely to have ever had HRT (78% versus 56%).
Unrecognized or poorly managed comorbid medical ill-
ness is a significant source of excess disability and mor-
tality in older persons with schizophrenia. The organi-
zation and delivery of care in a coordinated manner may
be a challenge.All these are important directions for new
research.
Antipsychotics in late-life schizophrenia
Use of conventional neuroleptic medications in older
patients is highly problematic,with observed incidence
rates of tardive dyskinesia in excess of 20% in the first
year of treatment and growing to over 50% in 3 years of
cumulative treatment.
47,48 Importantly, these findings
emerged in the context of very low dosing of the med-
ication. Therefore, safety and efficacy of the atypical
antipsychotic medications in older patients with schizo-
phrenia is an important consideration.The initial regis-
tration studies of the atypical antipsychotic medications
contained few older patients. To date, the only two
antipsychotic medications that have been specifically
investigated in a randomized clinical trial in patients over
age 60 are risperidone and olanzapine.
49These medica-
tions were compared in an 8-week,double-blind study of
elderly (age over 60) patients with schizophrenia.The
dosing of both medications was flexible,with a range of
1 to 3 mg/day for risperidone and 5 to 20 mg/day for
olanzapine. The primary outcome measures were the
change on the Positive And Negative Syndrome Scale
(PANSS) and rates of extrapyramidal symptoms (EPSs).
This investigation found that patients in both groups
showed significant improvement during the 8-week trial,
and that this improvement was similar for both treatment
groups. The rates of EPSs were also similar in both
groups.
Side effects of atypical antipsychotics in elderly patients
The safety and adverse events profile of atypical antipsy-
chotics in elderly patients treated is mixed.On the posi-
tive side,there is a significantly lower incidence of tardive
dyskinesia among older patients taking atypical antipsy-
chotics compared with the older typical antipsychotics.
There is widespread concern regarding the effect of atyp-
ical antipsychotics on cardiovascular and metabolic func-
tion, diabetes, and lipid levels, with resultant warnings
issued by various regulatory and professional organiza-
tions.It is beyond the scope of this paper to review the
substantial body of literature in these areas.
Particular safety concerns have been raised regarding the
use of atypical antipsychotics in older patients with
dementia.Elevated mortality rates have been reported
in placebo-controlled trials of atypical antipsychotics in
demented patients taking active drugs compared with
placebo.On the basis of the findings of a 1.6- to 1.7-fold
increase in the risk of mortality in patients with behav-
ioral disturbances due to dementia taking atypical
antipsychotics compared with placebo,alerts and warn-
ings have been issued in the USA,the UK,and Canada
with respect to use of all atypical antipsychotics in
demented patients. An increase in cerebrovascular
adverse events was also observed in these studies. It
should be noted that these studies were typically carried
out in nursing home settings in very old patients with a
variety of dementing disorders,and many of the patients
had elevated vascular risk factors, including history of
hypertension and stroke. Agitation and psychosis, the
behavioral disturbances of Alzheimer’s disease,and other
dementing disorders present difficult and complex clini-
cal management problems. Currently available treat-
ments,both pharmacological and behavioral,are far from
optimal,from both a safety and efficacy perspective.“No
treatment” is clearly not an option for many patients.
Therefore,great care must taken in use of any treatment,
and close monitoring is essential.
It remains unclear whether these concerns are specific to
older patients with dementias or whether they are gen-
eralizable to atypical antipsychotic use in all older
patients.With funding from the National Institutes of
Health,we have initiated a comprehensive prospective
study of a large sample (n=450) of older persons in whom
an atypical antipsychotic is identified as a treatment of
choice.Patients are randomized to one of four medica-
tions (aripiprazole,olanzapine,quetiapine,and risperi-
done),and assessed every 3 months for at least 2 years.
The protocol includes complete physical examinations,
periodic questionnaires and standardized rating scales,
and a variety of metabolic measures and markers of vas-
cular inflammation and endothelial dysfunction. This
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49study provides the opportunity to address the many
questions that are emerging about the use of atypical
antipsychotic medications in the older patient.
Conclusions
Schizophrenia in late life is a serious illness. It is pro-
foundly disabling for most people with the disease,and
care for these patients places great pressure on health
care systems.We have provided an overview of several
important issues in the field: the pressure created by
schizophrenia in late life on the health care system;the
epidemiology of the illness; the significance of age of
onset to clinical course and outcome,especially remis-
sion; the special concerns at the medicine–psychiatry
interface; and the efficacy and safety of antipsychotic
medications.We have raised issues of safety with respect
to use of atypical antipsychotics in older people with
dementias, and questioned the generalizability of this
concern to broader,nondemented clinical populations.
Finally,it is important to note that the pharmacological
treatments available for use in schizophrenia are far from
ideal.The drugs are expensive;remission,though possi-
ble,is uncommon;and patients are often in the position
of achieving some reduction in symptom severity but
rarely to the level of wellness. As was shown in the
recently completed Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) trial in the USA,
50
problems of tolerability and side effects interact such that
few patients actually stay with the drug treatment they
are prescribed, or, for that matter, with any treatment.
Clearly,we need better drugs and better approaches to
the discovery and development of drugs.
51At the same
time,we need to acknowledge the important statement
of the National Institute for Clinical Excellence (NICE)
in the UK: “… The management of schizophrenia
involves a comprehensive package of care,[…] drug ther-
apy accounts for less than 5% of the total health care
costs of schizophrenia.”
52 Future directions in research
and clinical care of older persons with schizophrenia
should include psychosocial interventions aimed at
improving functioning and illness management. ❏
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Esquizofrenia a edad avanzada: 
temas emergentes
La esquizofrenia a edad avanzada se está constitu-
yendo en un gran problema de salud pública a nivel
mundial. En este trabajo se discuten algunas áreas
de investigación y cuidados clínicos que son parti-
cularmente pertinentes a las personas ancianas con
esquizofrenia, incluyendo los desafíos de la salud
pública y los costos de atención. Además se discu-
ten temas clínicos relacionados con la esquizofrenia
en la edad avanzada (curso de la enfermedad y
aspectos cognitivos), los cuidados médicos y la
comorbilidad en pacientes psiquiátricos ancianos
(generales y en relación con la enfermedad), y tra-
tamientos relacionados con el empleo de antipsi-
cóticos atípicos en personas ancianas con psicosis
(eficacia y efectos colaterales). El cuidado clínico
para este segmento –siempre creciente– de nuestra
población, requiere de una consideración especial
por las características específicas que representan
las personas ancianas con esquizofrenia. 
Problèmes spécifiques de la schizophrénie
en fin de vie 
La schizophrénie dans la dernière partie de la vie
est en train de devenir un problème majeur de
santé publique dans le monde entier. Nous abor-
dons plusieurs domaines de la recherche et discu-
tons des soins cliniques particulièrement adaptés
aux personnes âgées atteintes de schizophrénie, y
compris du défi de santé publique que cela repré-
sente et des coûts des soins qui s’y rapportent. Nous
traitons ensuite les questions cliniques relatives à la
schizophrénie en fin de vie (évolution de la mala-
die, et cognition), les soins médicaux, et la comor-
bidité chez les patients psychiatriques âgés (en
général et liée à la maladie), et les problèmes thé-
rapeutiques liés à l’utilisation d’antipsychotiques
atypiques chez les personnes âgées psychotiques
(efficacité et effets indésirables). Les soins apportés
à cette partie de la population toujours croissante
requièrent spécialement notre attention en raison
de la caractéristique spécifique que représente le
sujet âgé schizophrène.
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